Biomerieux SA (BIM) - Total Liabilities
Based on the latest financial reports, Biomerieux SA (BIM) has total liabilities worth €1.43 Billion EUR (≈ $1.67 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIM cash flow metrics to assess how effectively this company generates cash.
Biomerieux SA - Total Liabilities Trend (2005–2024)
This chart illustrates how Biomerieux SA's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Biomerieux SA to evaluate the company's liquid asset resilience ratio.
Biomerieux SA Competitors by Total Liabilities
The table below lists competitors of Biomerieux SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nexchip Semiconductor Corp. A
SHG:688249
|
China | CN¥25.06 Billion |
|
Erie Indemnity Company
NASDAQ:ERIE
|
USA | $1.02 Billion |
|
CCL Industries Inc
TO:CCL-B
|
Canada | CA$4.92 Billion |
|
Shanghai International Airport Co Ltd
SHG:600009
|
China | CN¥25.68 Billion |
|
Xero Ltd
AU:XRO
|
Australia | AU$2.09 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €48.58 Million |
|
Viavi Solutions Inc
NASDAQ:VIAV
|
USA | $1.94 Billion |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
USA | $4.80 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Biomerieux SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIM market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.16 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomerieux SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomerieux SA (2005–2024)
The table below shows the annual total liabilities of Biomerieux SA from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.56 Billion ≈ $1.82 Billion |
+3.45% |
| 2023-12-31 | €1.51 Billion ≈ $1.76 Billion |
-2.38% |
| 2022-12-31 | €1.54 Billion ≈ $1.80 Billion |
+7.10% |
| 2021-12-31 | €1.44 Billion ≈ $1.69 Billion |
-0.35% |
| 2020-12-31 | €1.45 Billion ≈ $1.69 Billion |
-5.29% |
| 2019-12-31 | €1.53 Billion ≈ $1.79 Billion |
+1.66% |
| 2018-12-31 | €1.50 Billion ≈ $1.76 Billion |
+19.88% |
| 2017-12-31 | €1.25 Billion ≈ $1.47 Billion |
-10.96% |
| 2016-12-31 | €1.41 Billion ≈ $1.65 Billion |
+10.74% |
| 2015-12-31 | €1.27 Billion ≈ $1.49 Billion |
+6.65% |
| 2014-12-31 | €1.19 Billion ≈ $1.39 Billion |
+28.25% |
| 2013-12-31 | €929.30 Million ≈ $1.09 Billion |
+46.81% |
| 2012-12-31 | €633.00 Million ≈ $740.04 Million |
-3.92% |
| 2011-12-31 | €658.80 Million ≈ $770.21 Million |
+39.40% |
| 2010-12-31 | €472.60 Million ≈ $552.52 Million |
+4.26% |
| 2009-12-31 | €453.30 Million ≈ $529.96 Million |
-9.48% |
| 2008-12-31 | €500.80 Million ≈ $585.49 Million |
+26.11% |
| 2007-12-31 | €397.10 Million ≈ $464.25 Million |
+3.93% |
| 2006-12-31 | €382.10 Million ≈ $446.72 Million |
-6.26% |
| 2005-12-31 | €407.60 Million ≈ $476.53 Million |
-- |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more